Article PDF
... are common words in the language that appear both in day to day language as well as very commonly in clinical notes. We appended the English stop words used within the Terrier Package4 with some manually curated clinical stop words. The list of stop words used is published in https://github.com/ rxn ...
... are common words in the language that appear both in day to day language as well as very commonly in clinical notes. We appended the English stop words used within the Terrier Package4 with some manually curated clinical stop words. The list of stop words used is published in https://github.com/ rxn ...
OsteoStim® Cervical Allograft Systems
... All OsteoStim Cervical Allograft is processed in facilities ...
... All OsteoStim Cervical Allograft is processed in facilities ...
FIG 7: gingival index
... Systemically administered antibiotics reach more easily not only the microorganisms in the sick sites but also the ones hidden in the periodontal tissues and in the oral cavity. (Slots & Rosling 1983). This undoubtedly means an advantage because it allows to prevent reinfection from exogenous source ...
... Systemically administered antibiotics reach more easily not only the microorganisms in the sick sites but also the ones hidden in the periodontal tissues and in the oral cavity. (Slots & Rosling 1983). This undoubtedly means an advantage because it allows to prevent reinfection from exogenous source ...
quality account
... We recognise that in order to have both a positive and informative reporting system, we need to maintain a culture where staff feel able to report incidents without fear of reprisal or blame. An organisation with high incident reporting is a mark of a ‘high reliability’ organisation. Research shows ...
... We recognise that in order to have both a positive and informative reporting system, we need to maintain a culture where staff feel able to report incidents without fear of reprisal or blame. An organisation with high incident reporting is a mark of a ‘high reliability’ organisation. Research shows ...
Pharmacological Treatment of Urinary Incontinence C 14
... desired effects in relevant preclinical experiments or in healthy volunteers (or in experimental situations in patients). This information has been considered in our clinical drug recommendations, which are based on evaluations made using a modification of the Oxford system. The terminology used is ...
... desired effects in relevant preclinical experiments or in healthy volunteers (or in experimental situations in patients). This information has been considered in our clinical drug recommendations, which are based on evaluations made using a modification of the Oxford system. The terminology used is ...
From Innovation to Clinical Value An Evaluation of Innovative Neurological Medical Devices
... Nexstim Ltd. has potential to provide clinical value by the ability of the products TMS technology to navigate in the brain. Elminda Ltd.’s product built of an evidence based rehabilitation platform could enhance recovery of patients with neurological disorders on an individual basis. BrainsGate Ltd ...
... Nexstim Ltd. has potential to provide clinical value by the ability of the products TMS technology to navigate in the brain. Elminda Ltd.’s product built of an evidence based rehabilitation platform could enhance recovery of patients with neurological disorders on an individual basis. BrainsGate Ltd ...
8 th International Congress on Drug Therapy in HIV
... termination of APL development has been previously reported. Previously unreported efficacy data are presented. Methods: 145 therapy naive subjects harboring R5-tropic virus, with screening vRNA >10,000 c/mL and CD4+≥ 100 cells/mm3, were randomized 2:2:1 to receive APL 600mg BID, APL 800mg BID, or E ...
... termination of APL development has been previously reported. Previously unreported efficacy data are presented. Methods: 145 therapy naive subjects harboring R5-tropic virus, with screening vRNA >10,000 c/mL and CD4+≥ 100 cells/mm3, were randomized 2:2:1 to receive APL 600mg BID, APL 800mg BID, or E ...
JOURNAL OF THE ASSOCIATION OF NEUROPHYSIOLOGICAL
... She is the ANS Council NI representative, and I thought it would be helpful for us to know a bit more about the set up there, which differs to mainland UK (which also has differences between the three countries – I am hopeful that similar overviews might be forthcoming from representatives in each c ...
... She is the ANS Council NI representative, and I thought it would be helpful for us to know a bit more about the set up there, which differs to mainland UK (which also has differences between the three countries – I am hopeful that similar overviews might be forthcoming from representatives in each c ...
HƯỚNG DẪN VỀ DƯỢC PHẨM INCIVEK
... combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null respon ...
... combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null respon ...
AusPAR: Ocriplasmin - Therapeutic Goods Administration
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. ...
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. ...
Tacrolimus vs. Azathioprine in myasthenia gravis treatment. A multicenter, prospective, randomized, double
... and even some studies show that FK506 (Tacrolimus) is significantly effective only 2 weeks after the administration (17). Ponseti et al. (16) concluded in their article that 9/13 patients evaluated achieved pharmacological remission (no symptoms during one year, except ocular fatigability) during th ...
... and even some studies show that FK506 (Tacrolimus) is significantly effective only 2 weeks after the administration (17). Ponseti et al. (16) concluded in their article that 9/13 patients evaluated achieved pharmacological remission (no symptoms during one year, except ocular fatigability) during th ...
II) 找尋最有用的證據
... INTRODUCTION AND OBJECTIVES: Moderate-to-severe hypertension is less prevalent than mild hypertension, but it is responsible for more incidences of complications. Its complex treatment requires several drugs, and is often inadequate. This study assessed the efficacy and safety of nifedipine GITS (or ...
... INTRODUCTION AND OBJECTIVES: Moderate-to-severe hypertension is less prevalent than mild hypertension, but it is responsible for more incidences of complications. Its complex treatment requires several drugs, and is often inadequate. This study assessed the efficacy and safety of nifedipine GITS (or ...
CANCER AND LEUKEMIA GROUP B CALGB 30801 A
... and 5-LOX as both single agents and in combination. A pilot trial at the University of Maryland demonstrated that the combination of celecoxib and zileuton was well tolerated when combined with either carboplatin/gemcitabine or carboplatin/paclitaxel. CALGB 30203 enrolled 140 patients in under one y ...
... and 5-LOX as both single agents and in combination. A pilot trial at the University of Maryland demonstrated that the combination of celecoxib and zileuton was well tolerated when combined with either carboplatin/gemcitabine or carboplatin/paclitaxel. CALGB 30203 enrolled 140 patients in under one y ...
Ocuflox - Allergan
... Nonteratogenic Effects Additional studies in rats with doses up to 360 mg/kg/day during late gestation showed no adverse effect on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn. There are, however, no adequate and well-controlled studies in pregnant ...
... Nonteratogenic Effects Additional studies in rats with doses up to 360 mg/kg/day during late gestation showed no adverse effect on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn. There are, however, no adequate and well-controlled studies in pregnant ...
AusPAR Dexamethasone - Therapeutic Goods Administration
... disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without fir ...
... disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without fir ...
lynda s. welage - University of Minnesota College of Pharmacy
... framework programmatic decision making and financial investment. Legislative Advocacy: Worked to restore state funding for New Mexico Poison and Drug Information Center (February 2012). Advocated to permanently recognize the need for the New Mexico Poison and Drug Information Center. This led to t ...
... framework programmatic decision making and financial investment. Legislative Advocacy: Worked to restore state funding for New Mexico Poison and Drug Information Center (February 2012). Advocated to permanently recognize the need for the New Mexico Poison and Drug Information Center. This led to t ...
2. Clinical Evaluation of Patients with Dysphagia: Importance of
... risk for dysphagia. Patients with these known diseases or medical treatments should be considered high risk for dysphagia. Ideally, a Speech-Language Pathologist using a standardized CSE would assess all of these patients. Unfortunately, hospital resources are often limited and this specialized care ...
... risk for dysphagia. Patients with these known diseases or medical treatments should be considered high risk for dysphagia. Ideally, a Speech-Language Pathologist using a standardized CSE would assess all of these patients. Unfortunately, hospital resources are often limited and this specialized care ...
Protocol S1.
... Results of the Phase III studies have demonstrated that GARDASIL™ is highly efficacious in preventing HPV 6-, HPV 11-, HPV 16-, and HPV 18-related CIN, AIS, cervical cancer (via CIN 2/3 and AIS), VIN, VaIN, condylomata acuminata, vulvar cancer (via VIN 2/3), and vaginal cancer (via VaIN 2/3) in the ...
... Results of the Phase III studies have demonstrated that GARDASIL™ is highly efficacious in preventing HPV 6-, HPV 11-, HPV 16-, and HPV 18-related CIN, AIS, cervical cancer (via CIN 2/3 and AIS), VIN, VaIN, condylomata acuminata, vulvar cancer (via VIN 2/3), and vaginal cancer (via VaIN 2/3) in the ...
Special Report: Companion BRAF Mutation Testing to Select Patients with
... BRAF V600 Mutation Test is provided by the Phase III clinical trial of vemurafenib, which also supported the FDA approval of the drug. In addition, evidence from Phase I and Phase II trials was reviewed. All trials used enrichment trial designs, in which patient enrollment was based on a positive re ...
... BRAF V600 Mutation Test is provided by the Phase III clinical trial of vemurafenib, which also supported the FDA approval of the drug. In addition, evidence from Phase I and Phase II trials was reviewed. All trials used enrichment trial designs, in which patient enrollment was based on a positive re ...
Innovative Medicines Division
... Source: Novartis (Apr 2016). Note that only PsO and PsA are approved in Japan & Maylasia (not AS) ...
... Source: Novartis (Apr 2016). Note that only PsO and PsA are approved in Japan & Maylasia (not AS) ...
(PSD) November 2015 PBAC Meeting
... chronic idiopathic urticaria (CIU), including efficacy in patients who have failed multiple other treatments and lower toxicity than other treatments and therefore less ...
... chronic idiopathic urticaria (CIU), including efficacy in patients who have failed multiple other treatments and lower toxicity than other treatments and therefore less ...
Study 33: Analysing a cross-over study. Statistical work and
... contains more general and more detailed sections describing relevant statistical aspects. Study 33 was carried out as a double blinded, randomized crossover study in healthy volunteers with the primary objective:“The primary objective for this study will be to compare sedation, one hour after first ...
... contains more general and more detailed sections describing relevant statistical aspects. Study 33 was carried out as a double blinded, randomized crossover study in healthy volunteers with the primary objective:“The primary objective for this study will be to compare sedation, one hour after first ...
PH1835 Downloads\Subgroup Analyses
... group were beneficiaries of this 25% benefit, and that the beneficial effect of therapy provides protection that is broadly distributed (Figure 10.1, panel 1.) This treatment effect uniformity is the truth about the population at large. However, the examination of the same therapy effect within diff ...
... group were beneficiaries of this 25% benefit, and that the beneficial effect of therapy provides protection that is broadly distributed (Figure 10.1, panel 1.) This treatment effect uniformity is the truth about the population at large. However, the examination of the same therapy effect within diff ...
Instructions For Use
... The ADVANCE study was a single-cohort, open-label trial that enrolled 50 patients with either unilateral or bilateral ethmoid sinus disease at 7 study centers. Follow-up assessments included endoscopic examination and scoring through 2 months, with patient symptom scoring done through 6 months (Sino ...
... The ADVANCE study was a single-cohort, open-label trial that enrolled 50 patients with either unilateral or bilateral ethmoid sinus disease at 7 study centers. Follow-up assessments included endoscopic examination and scoring through 2 months, with patient symptom scoring done through 6 months (Sino ...